Co-sponsored Luncheon Seminar

Co-sponsored Luncheon Seminar 1
A Focused Approach: Targeting Muscarinic Receptors in Schizophrenia

2024年5月23日(木) 12:30 〜 13:30 Room 1 (Hall C)

Chair: Prakash Masand(Duke-NUS Academic Medicine Education Institute)

Co-sponsored by Bristol Myers Squibb

[CLS1] A Focused Approach: Targeting Muscarinic Receptors in Schizophrenia

*Bristol Myers Squibb

Co-sponsored Luncheon Seminar

Co-sponsored Luncheon Seminar 2
Current challenges and implications of cognitive performance for clinical practice in the treatment of major depressive disorder

2024年5月24日(金) 12:15 〜 13:15 Room 2 (Hall B7 (1))

Chair: Hikaru Hori (Faculty of medicine,Department of psychiatry, Fukuoka University)

Co-sponsored by Takeda Pharmaceutical Company Limited / Lundbeck Japan K.K.

[CLS2] Current challenges and implications of cognitive performance for clinical practice in the treatment of major depressive disorder

*Bernhard Baune¹ (1. University of Münster, University of Melbourne, The Florey Institute of Neuroscience and Mental Health)

Co-sponsored Luncheon Seminar

Co-sponsored Luncheon Seminar 3
Potential targets for the treatment of depression: The inflammatory hypothesis.

2024年5月24日(金) 12:15 〜 13:15 Room 4 (Hall D1)

Chair: Hiroyuki Uchida (Department of Neuropsychiatry, Keio University School of Medicine)

Co-sponsored by Viatris Pharmaceauticals Japan Inc.

[CLS3] Potential targets for the treatment of depression: The inflammatory hypothesis.

*Masaaki Iwata¹ (1. Department of Neuropsychiatry, Brain and Neurosciences, Faculty of Medicine Tottori university)

Co-sponsored Luncheon Seminar

Co-sponsored Luncheon Seminar 4
How to proceed in the management of treat resistant depression -The Possibility of Rexulti-

2024年5月24日(金) 12:15 〜 13:15 Room 12 (Hall D5)

Chair: Ken Inada (Kitasato University)

Co-sponsored by Otsuka Pharmaceutical Co., Ltd.

[CLS4] 難治性うつ病治療の進め方　-レキサルティの可能性-

*加藤正樹¹ (1. 関西医科大学)

Co-sponsored Luncheon Seminar

Co-sponsored Luncheon Seminar 5
An update on current understanding of tardive dyskinesia: epidemiology, pathology, and burden of patients

2024年5月24日(金) 12:15 〜 13:15 Room 13 (G701)

Chair: Masaomi Iyo (International University of Health and Welfare Graduate School)

Co-sponsored by Mitsubishi Tanabe Pharma Corporation/Janssen Pharmaceutical K.K.

+全てマイスケジュールに登録

[CLS5-1] 遅発性ジスキネジアは精神医療現場でなぜ見て見ぬふりされていたのか？医療者としての心構えを国内外のデータベース研究から学ぶ

*加藤隆弘¹ (1. 九州大学大学院医学研究院精神病態医学)

[CLS5-2] 遅発性ジスキネジアが生活に与える影響

*竹内啓善¹ (1. 慶應義塾大学医学部　精神・神経科学教室)

Co-sponsored Luncheon Seminar

Co-sponsored Luncheon Seminar 6
Rethinking medication for schizophrenia

2024年5月24日(金) 12:15 〜 13:15 Room 14 (G602)

Chair: Kotaro Hatta (Department of Psychiatry, Juntendo University Nerima Hospital )

Co-sponsored by Sumitomo Pharma Co., Ltd.

+全てマイスケジュールに登録

[CLS6-1] PET研究から考える統合失調症の薬物療法について

*舘野周¹ (1. 日本医科大学大学院医学研究科　精神・行動医学分野　大学院教授)

[CLS6-2] 統合失調症に対するユーザーフレンドリーな精神科薬物療法：経皮吸収型抗精神病薬が果たしうる役割

*鈴木健文¹ (1. 山梨大学医学部　精神神経医学講座　教授)

Co-sponsored Luncheon Seminar

Co-sponsored Luncheon Seminar 7
Perspective of digital biomarkers in mood disorders

2024年5月24日(金) 12:15 〜 13:15 Room 15 (G610)

Chair: Taishiro Kishimoto (Hills Joint Research Laboratory for Future Preventive Medicine and Wellness, Keio University School of Medicine)

Co-sponsored by Mochida Pharmaceutical Co., Ltd.

[CLS7] 気分障害におけるデジタルバイオマーカーの今後の展望

*高江洲義和¹ (1. 琉球大学大学院医学研究科精神病態医学講座)

Co-sponsored Luncheon Seminar

Co-sponsored Luncheon Seminar 8
The New Frontier in Pharmacotherapy for Depression: Moving Beyond the Monoamine Hypothesis

2024年5月24日(金) 12:15 〜 13:15 Room 16 (G502)

Chair: Yukio Ago (Department of Cellular and Molecular Pharmacology, Graduate School of Biomedical and Health Sciences, Hiroshima University)

Co-sponsored by Shionogi & Co., Ltd.

[CLS8] うつ病薬物治療の新時代　～モノアミンの先にある挑戦～

*櫻井準¹ (1. 杏林大学医学部精神神経科学教室)

Co-sponsored Luncheon Seminar

Co-sponsored Luncheon Seminar 9
Disease modifying therapies of Alzheimer's disease

2024年5月25日(土) 11:40 〜 12:40 Room 1 (Hall C)

Chair: Atsushi Iwata (Tokyo Metropolitan Institute for Geriatrics and Gerontology)

Co-sponsored by Eisai co., Ltd. / BiogenJapan Ltd.

[CLS9] Disease modifying therapies of Alzheimer's disease

*Takeshi Iwatsubo^1,2 (1. Department of Neuropathology, Graduate School of Medicine, The University of Tokyo, 2. National Institute of Neuroscience, National Center of Neurology and Psychiatry)

Co-sponsored Luncheon Seminar

Co-sponsored Luncheon Seminar 10
Challenges and Management of MDD in Working population and Elderly Patients

2024年5月25日(土) 11:40 〜 13:00 Room 2 (Hall B7 (1))

Chair: Masaki Kato (Department of Neuropsychiatry, Kansai Medical University, Japan)

Co-sponsored by H. Lundbeck A/S

+全てマイスケジュールに登録

[CLS10-1] What is the optimal way to manage MDD in working individuals?

*Toshiaki Kikuchi¹ (1. Keio University)

[CLS10-2] What can we learn from patient perspectives to improve our approach to treating emotional blunting in MDD?

*Michael MC Wong¹ (1. The University of Hong Kong, Hong Kong SAR)

[CLS10-3] How can we best manage MDD in elderly patients with comorbidities?

*Dong Woo Kang^1,2 (1. The Catholic University of Korea, Seoul, Korea, 2. Seoul St. Mary’s hospital, Seoul, Korea)

Co-sponsored Luncheon Seminar

Co-sponsored Luncheon Seminar 11
Master of Guanfacine -Towards ADHD Treatment Based on Brain Pathophysiology-

2024年5月25日(土) 11:40 〜 12:40 Room 12 (Hall D5)

Chair: Takashi Tsuboi (Department of Neuropsychiatry, Kyorin University School of Medicine)

Co-sponsored by Takeda Pharmaceutical Company Limited.

[CLS11] グアンファシンを究める-脳病態に基づいたADHD治療を目指して-

*國井泰人¹ (1. 東北大学災害科学国際研究所　災害精神医学分野　准教授)

Co-sponsored Luncheon Seminar

Co-sponsored Luncheon Seminar 12
Parkinson’s disease :The approaches to disease modification

2024年5月25日(土) 11:40 〜 12:40 Room 13 (G701)

Chair: Nobutaka Hattori (Department of Neurology, Juntendo University Faculty of Medicine )

Co-sponsored by Ono Pharmaceutical Co., Ltd.

[CLS12] パーキンソン病：疾患修飾へのアプローチ

*小野賢二郎¹ (1. 金沢大学脳神経内科学)

Co-sponsored Luncheon Seminar

Co-sponsored Luncheon Seminar 13
Treatment strategy for major depressive disorder focusing on anxiety symptoms

2024年5月25日(土) 11:40 〜 12:40 Room 14 (G602)

Chair: Tempei Otsubo (Department of Psychiatry, Tokyo Women's Medical University Adachi Medical Center)

Co-sponsored by Viatris Pharmaceauticals Japan Inc.

[CLS13] 不安症状に着目したうつ病治療戦略

*高江洲義和¹ (1. 琉球大学大学院医学研究科精神病態医学講座)

Co-sponsored Luncheon Seminar

Co-sponsored Luncheon Seminar 14
Future Challenges for Psychiatric Pharmacotherapy

2024年5月25日(土) 11:40 〜 12:40 Room 15 (G610)

Chair: Nakao Iwata (Department of Psychiatry, Fujita Health University School of Medicine)

Co-sponsored by Sumitomo Pharma Co., Ltd.

[CLS14] 精神科薬物療法のこれから

*久住一郎¹ (1. 医療法人奏和会苫小牧緑ヶ丘病院)

Co-sponsored Luncheon Seminar

Co-sponsored Luncheon Seminar 15
Toward Better Clinical Use of Asenapine - An Overview of the Evidence for Asenapine-

2024年5月25日(土) 11:40 〜 12:40 Room 16 (G502)

Chair: Ken Inada (Department of Psychiatry, Kitasato University School of Medicine)

Co-sponsored by Meiji Seika Pharma Co., Ltd.

[CLS15] Asenapineのより良い臨床使用に向けて　～エビデンスを概観する～

*嶽北佳輝¹ (1. 関西医科大学医学部精神神経科学講座)

Co-sponsored Luncheon Seminar

Co-sponsored Luncheon Seminar 16
Evidence and prospect for practice of LAI

2024年5月25日(土) 11:40 〜 12:40 Room 17 (G510)

Chair: Itaru Miura (Fukushima Medical University)

Co-sponsored by Janssen Pharmaceutical K.K.

[CLS16] LAIのエビデンスと実践への展望

*三澤史斉¹ (1. 地方独立行政法人山梨県立病院機構山梨県立北病院)

Co-sponsored Luncheon Seminar

Co-sponsored Luncheon Seminar 17
State-of-the-art strategies for diagnosing and treating tardive dyskinesia

2024年5月26日(日) 12:15 〜 13:15 Room 1 (Hall C)

Chair: Takefumi Suzuki (Department of Neuropsychiatry, University of Yamanashi Faculty of Medicine, Yamanashi)

Co-sponsored by Mitsubishi Tanabe Pharma Corporation / Janssen Pharmaceutical K.K.

[CLS17] State-of-the-art strategies for diagnosing and treating tardive dyskinesia

*John M. Kane¹ (1. Psychiatry and Molecular Medicine at the Donald and Barbara Zucker School of Medicine)

Co-sponsored Luncheon Seminar

Co-sponsored Luncheon Seminar 18
Treatment to cognitive dysfunction in schizophrenia

2024年5月26日(日) 12:15 〜 13:15 Room 12 (Hall D5)

Chair: Ken Inada (Department of Psychiatry, Kitasato University School of Medicine)

Co-sponsored by Sumitomo Pharma Co., Ltd. Medical Science

[CLS18] 統合失調症の認知機能障害に対する対応

*堀輝¹ (1. 福岡大学医学部精神医学教室)

Co-sponsored Luncheon Seminar

Co-sponsored Luncheon Seminar 19
Coping with Sleep Disorders: Significance to the Mind, Brain, and Body

2024年5月26日(日) 12:15 〜 13:15 Room 13 (G701)

Chair: Yoshikazu Takaesu (Department of Neuropsychiatry, Graduate School of Medicine, University of the Ryukyus)

Co-sponsored by Eisai. Co., Ltd.

[CLS19] 睡眠障害への対応：こころ・脳・身体に対する意義を踏まえて

*尾崎紀夫¹ (1. 名古屋大学・大学院医学系研究科　精神疾患病態解明学)

Co-sponsored Luncheon Seminar

Co-sponsored Luncheon Seminar 20
The Current Status of Hypnotic Prescribing in Japan, Future Challenges and Prospects

2024年5月26日(日) 12:15 〜 13:15 Room 14 (G602)

Chair: Hitoshi Sakurai (Department of Neuropsychiatry, Kyorin University Faculty of Medicine)

Co-sponsored by MSD K.K.

[CLS20] 日本の睡眠薬処方の実態と今後の課題、展望

*竹島正浩¹ (1. 秋田大学大学院医学系研究科　精神科学講座　准教授)

セッション一覧

Co-sponsored Symposium / Seminar » Co-sponsored Luncheon Seminar

Co-sponsored Luncheon Seminar 1A Focused Approach: Targeting Muscarinic Receptors in Schizophrenia

Co-sponsored Luncheon Seminar 2Current challenges and implications of cognitive performance for clinical practice in the treatment of major depressive disorder

Co-sponsored Luncheon Seminar 3Potential targets for the treatment of depression: The inflammatory hypothesis.

Co-sponsored Luncheon Seminar 4How to proceed in the management of treat resistant depression -The Possibility of Rexulti-

Co-sponsored Luncheon Seminar 5An update on current understanding of tardive dyskinesia: epidemiology, pathology, and burden of patients

Co-sponsored Luncheon Seminar 6Rethinking medication for schizophrenia

Co-sponsored Luncheon Seminar 7Perspective of digital biomarkers in mood disorders

Co-sponsored Luncheon Seminar 8The New Frontier in Pharmacotherapy for Depression: Moving Beyond the Monoamine Hypothesis

Co-sponsored Luncheon Seminar 9Disease modifying therapies of Alzheimer's disease

Co-sponsored Luncheon Seminar 10Challenges and Management of MDD in Working population and Elderly Patients

Co-sponsored Luncheon Seminar 11Master of Guanfacine -Towards ADHD Treatment Based on Brain Pathophysiology-

Co-sponsored Luncheon Seminar 12Parkinson’s disease :The approaches to disease modification

Co-sponsored Luncheon Seminar 13Treatment strategy for major depressive disorder focusing on anxiety symptoms

Co-sponsored Luncheon Seminar 14Future Challenges for Psychiatric Pharmacotherapy

Co-sponsored Luncheon Seminar 15Toward Better Clinical Use of Asenapine - An Overview of the Evidence for Asenapine-

Co-sponsored Luncheon Seminar 16Evidence and prospect for practice of LAI

Co-sponsored Luncheon Seminar 17State-of-the-art strategies for diagnosing and treating tardive dyskinesia

Co-sponsored Luncheon Seminar 18Treatment to cognitive dysfunction in schizophrenia

Co-sponsored Luncheon Seminar 19Coping with Sleep Disorders: Significance to the Mind, Brain, and Body

Co-sponsored Luncheon Seminar 20The Current Status of Hypnotic Prescribing in Japan, Future Challenges and Prospects

認証

Co-sponsored Luncheon Seminar 1
A Focused Approach: Targeting Muscarinic Receptors in Schizophrenia

Co-sponsored Luncheon Seminar 2
Current challenges and implications of cognitive performance for clinical practice in the treatment of major depressive disorder

Co-sponsored Luncheon Seminar 3
Potential targets for the treatment of depression: The inflammatory hypothesis.

Co-sponsored Luncheon Seminar 4
How to proceed in the management of treat resistant depression -The Possibility of Rexulti-

Co-sponsored Luncheon Seminar 5
An update on current understanding of tardive dyskinesia: epidemiology, pathology, and burden of patients

Co-sponsored Luncheon Seminar 6
Rethinking medication for schizophrenia

Co-sponsored Luncheon Seminar 7
Perspective of digital biomarkers in mood disorders

Co-sponsored Luncheon Seminar 8
The New Frontier in Pharmacotherapy for Depression: Moving Beyond the Monoamine Hypothesis

Co-sponsored Luncheon Seminar 9
Disease modifying therapies of Alzheimer's disease

Co-sponsored Luncheon Seminar 10
Challenges and Management of MDD in Working population and Elderly Patients

Co-sponsored Luncheon Seminar 11
Master of Guanfacine -Towards ADHD Treatment Based on Brain Pathophysiology-

Co-sponsored Luncheon Seminar 12
Parkinson’s disease :The approaches to disease modification

Co-sponsored Luncheon Seminar 13
Treatment strategy for major depressive disorder focusing on anxiety symptoms

Co-sponsored Luncheon Seminar 14
Future Challenges for Psychiatric Pharmacotherapy

Co-sponsored Luncheon Seminar 15
Toward Better Clinical Use of Asenapine - An Overview of the Evidence for Asenapine-

Co-sponsored Luncheon Seminar 16
Evidence and prospect for practice of LAI

Co-sponsored Luncheon Seminar 17
State-of-the-art strategies for diagnosing and treating tardive dyskinesia

Co-sponsored Luncheon Seminar 18
Treatment to cognitive dysfunction in schizophrenia

Co-sponsored Luncheon Seminar 19
Coping with Sleep Disorders: Significance to the Mind, Brain, and Body

Co-sponsored Luncheon Seminar 20
The Current Status of Hypnotic Prescribing in Japan, Future Challenges and Prospects